#United States #Fort Lee #Rare Disease #Kedrion Biopharma #ISTH

Kedrion Biopharma's Significant Contributions to Rare Disease Research at ISTH 2026

Kedrion Biopharma, a leading biopharmaceutical company specializing in plasma-derived therapies, made noteworthy strides in advancing the understanding of rare diseases at the recent International Society on Thrombosis and Haemostasis (ISTH) Congress held in Paris. This year, the company focused on enhancing patient outcomes by presenting new scientific insights and promoting knowledge sharing among experts in the field.

During the conference, Kedrion emphasized the importance of scientific leadership in fostering advancements in patient care. Bob Rossilli, the Chief Commercial Officer, stated, "Scientific leadership is an essential part of how we deliver for patients. By investing in clinical research and collaborating with experts, we're helping advance the understanding of rare diseases."

The significance of early diagnosis and personalized treatment continues to be a major challenge in the realm of rare diseases. Kedrion's initiative aimed at facilitating scientific dialogue to boost disease recognition and improve clinical decision-making, ultimately benefiting patients with rare conditions. Through rigorous research efforts and supportive collaborations, the company seeks to fill knowledge gaps in diagnosis and management for those living with these conditions.

Alongside its presentations at ISTH, Kedrion addressed key issues in the management of ultra-rare diseases, such as Plasminogen Deficiency Type 1 (PLGD-1) and Hereditary Factor X Deficiency (HFXD). These discussions revolved around the impact of gender on disease burden and patient quality of life, emphasizing that recognition plays a crucial role in providing appropriate care.

Dr. Karen Thibaudeau, Global Medical Therapeutic Area Lead for Plasminogen Deficiency, highlighted an essential study exploring the timelines for diagnosing PLGD-1. The findings underscored the delays patients face from symptom onset to diagnosis, emphasizing the need for awareness to facilitate earlier recognition and timely intervention. Through detailed presentations, Kedrion reinforced its commitment to translating these insights into better healthcare practices for patients worldwide.

One of the many impactful discussions at the conference focused on the symposium regarding HFXD. Here, the emphasis was placed particularly on how symptoms in women and children are often overlooked, leading to delays in diagnosis and treatment. Dr. Beatrice Nolan, a specialist in pediatric hematology, articulated the unique challenges faced by pediatric patients diagnosed with HFXD, underlining the necessity of gender-sensitive approaches in clinical care.

Kedrion's presentations not only explored the clinical management of these diseases but also reflected their dedication to raising awareness about the specific issues faced by patients suffering from them. Renowned hematologists participating in the educational sessions discussed often-neglected aspects of plasminogen deficiency, such as its severe neonatal symptoms and impact on quality of life. Experts advocated for greater clinician awareness to ensure patients receive appropriate evaluations and care from early childhood through adulthood.

In conclusion, Kedrion's active participation at the ISTH 2026 highlights a profound commitment to addressing the unmet medical needs of patients with rare diseases. Their collaborative approach facilitates a broader dialogue within the medical community, ultimately aiming to improve outcomes for these patients. As the field continues to evolve, Kedrion remains steadfast in its mission to implement findings from clinical research into concrete strategies that enhance patient care.

For more insight into Kedrion’s efforts and their ongoing initiatives in rare disease awareness, visit Kedrion's website.